First magnetic resonance imaging-guided cardiac radioablation of sustained ventricular tachycardia.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 10 2019
revised: 16 12 2019
accepted: 09 01 2020
pubmed: 19 2 2020
medline: 15 4 2021
entrez: 19 2 2020
Statut: ppublish

Résumé

To report the feasibility of magnetic resonance imaging-guided cardiac single fraction radioablation (MRgRA) in a patient with dilated cardiomyopathy and recurrent sustained ventricular tachycardia (VT) leading to electrical storms (ES). A workflow to perform Stereotactic Arrhythmia Radioablation (STAR) on a hybrid MR-Linac with real-time tracking and beam-gating was established. Challenges of the MRgRA approach included: (a) the safety of a non-MR compatible cardiac implantable electronic device (CIED) in the MR-Linac field, (b) artefacts caused by the CIED and (c) respiratory motion management with cine-tracking of the moving heart. The specific absorption rate and slew rate of the MR-Linac were within the specifications of a MR-conditional CIED. Phantom measurements showed CIED distortion artefacts of less than 1.5 mm. During MR simulation, tracking could be established on the upper liver to avoid interference with the moving heart and CIED extinction artefacts. Areas of anatomical scarring and critical substrate were identified using invasive three-dimensional electroanatomical mapping of the clinical VT during electrophysiological studies and cardiac MR imaging/computed tomography to build a volumetric target. A 71-year-old male patient with non-ischemic dilated cardiomyopathy and recurrent therapy-refractory sustained VT with repetitive implantable cardioverter-defibrillator (ICD) shocks was treated with a single fraction of 25 Gy @85% isodose, cine-tracking time was 46 min, beam-on time 24 min. 24 h post intervention the patient developed an aggravation of the clinical VT and prolonged ES. VT ceased following high-dose dexamethasone administration after 48 h. After this point, the patient remained without any episodes of sustained ventricular tachyarrhythmia requiring ICD interventions until the last follow-up at three months. Real-time tracking and beam-gating were successfully applied in this first MRgRA to treat sustained VT.

Identifiants

pubmed: 32067819
pii: S0167-8140(20)30020-7
doi: 10.1016/j.radonc.2020.01.008
pii:
doi:

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-207

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Michael Mayinger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Boldizsar Kovacs (B)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Stephanie Tanadini-Lang (S)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Stefanie Ehrbar (S)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Lotte Wilke (L)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Madalyne Chamberlain (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Amanda Moreira (A)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Nienke Weitkamp (N)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Corinna Brunckhorst (C)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Firat Duru (F)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Jan Steffel (J)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Alexander Breitenstein (A)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Hatem Alkadhi (H)

Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland.

Helena I Garcia Schueler (HI)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Robert Manka (R)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland; Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland.

Frank Ruschitzka (F)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Ardan M Saguner (AM)

University Heart Center Zurich, University Hospital Zurich, University of Zurich, Switzerland.

Nicolaus Andratschke (N)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH